etanercept (Enbrel)

following an abbreviated submission:

etanercept (Enbrel®) is accepted for restricted use within NHS Scotland.

Indication under review: for the treatment of -

• polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate;
• psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate;
• enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy.

SMC restriction: use within specialist rheumatology services (including those working within the network for paediatric rheumatology).

Etanercept has previously been accepted by the SMC for the treatment of active polyarticular juvenile idiopathic arthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate.

Etanercept is listed in the British National Formulary for Children 2011-2012 as one of a number of treatment options for juvenile idiopathic arthritis including the above subtypes.